Accurexa Inc (ACXA) 0.5500 $ACXA Accurexa Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Accurexa Inc (ACXA) 0.5500 $ACXA

Accurexa Announces Positive FDA Pre-IND Meeting Outcome for its ACX-31 Brain Cancer Program
ACCESSWIRE - Tue Aug 16, 11:20AM CDT
NEWARK, DE / ACCESSWIRE / August 16, 2016 / Accurexa Inc. (the "Company" or "Accurexa" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it received a written response from the FDA (U.S. Food and Drug Administration) regarding a pre-IND (Investigational New Drug) meeting request for its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU, both chemotherapeutics, in the treatment of brain tumors in conjunction with surgery and radiation. The FDA confirmed the acceptability of a 505(b)(2) application pathway with one first-in-human Phase 2 clinical trial followed by one Phase 3 clinical trial.

Accurexa Submits Pre-IND Meeting Request to the U.S. FDA for Its ACX-31 Program
ACCESSWIRE - Wed Jun 22, 8:00AM CDT
NEWARK, DE / ACCESSWIRE / June 22, 2016 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. FDA (Food and Drug Administration) for its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU, both chemotherapeutics, in the treatment of brain tumors in conjunction with surgery and radiation. A pre-IND meeting typically occurs within 60 days of the FDA receipt of the written meeting request per FDA's own guidance.

UCSF and Accurexa Receive Response From FDA to Pre-IND Meeting Request
ACCESSWIRE - Thu Mar 24, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / March 24, 2016 / the "Company" or "Accurexa" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that the University of California, San Francisco ("UCSF" received a written response from the FDA (U.S. Food and Drug Administration) regarding a pre-IND meeting request to discuss a collaborative program between UCSF and Accurexa to evaluate a combined stem cell/gene transfer candidate therapeutic CNS10-NPC GDNF for the treatment of Parkinson's Disease using Accurexa's BranchPoint delivery device. CNS10-NPC are human fetal neural stem cells that express Glial-Derived Neurotrophic Factor (GDNF) in the treatment of Parkinson's Disease, and are expected to be supplied by the Cedars-Sinai Regenerative Medicine Institute in support of IND (Investigational New Drug) enabling studies.

Accurexa Initiates Preparation of Pre-IND Meeting for its ACX-31 Program
ACCESSWIRE - Thu Mar 17, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / March 17, 2016 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it has initiated the preparation of a pre-IND meeting for its ACX-31 program for the local delivery of temozolomide in combination with BCNU, both chemotherapeutics, in the treatment of brain tumors.

Accurexa Engages PharmaLex to Advance its ACX-31 Program towards a Regulatory Path
ACCESSWIRE - Wed Feb 10, 7:03AM CST
NEWARK, DE / ACCESSWIRE / February 10, 2016 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it has engaged PharmaLex Development Services, LLC ("PharmaLex" to advise the Company in the development of its ACX-31 program for the local delivery of temozolomide in combination with BCNU, both chemotherapeutics, in the treatment of brain tumors.

"New To The Street" to Air New Interviews on FOX Business Network
Marketwired - Tue Dec 01, 2:09PM CST
"New To The Street" will be broadcasting its latest show nationwide on FOX Business, Sunday, December 13, 2015 at 4:30 pm, potentially reaching 83.1 million households.
TWTR: 18.67 (+0.12)

UCSF and Accurexa Request Pre-IND Meeting with FDA
ACCESSWIRE - Wed Nov 04, 7:01AM CST
NEWARK, DE / ACCESSWIRE / November 4, 2015 / Accurexa Inc. (the "Company" or "Accurexa" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that the University of California, San Francisco ("UCSF" requested a pre-IND meeting with the FDA to discuss a collaborative program between UCSF and Accurexa to evaluate a combined stem cell/gene transfer candidate therapeutic CNS10-NPC GDNF for the treatment of Parkinson's Disease using Accurexa's BranchPoint delivery device. CNS10-NPC are human fetal neural stem cells that express Glial-Derived Neurotrophic Factor (GDNF) in the treatment of Parkinson's Disease, and are expected to be supplied by the Cedars-Sinai Regenerative Medicine Institute in support of IND (Investigational New Drug) enabling studies.

Accurexa Enters into Collaboration with The Hebrew University of Jerusalem
ACCESSWIRE - Mon Nov 02, 7:02AM CST
NEWWARK, DE / ACCESSWIRE / November 2, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it entered into an agreement with the Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. ("Yissum" to develop and supply a polymeric formulation of a combination of carmustine and temozolomide for sustained local administration to a solid tumor (the "Services". The Services will be provided by Yissum under a service agreement under which the Company will retain ownership of all intellectual property rights that are discovered or developed during the course of the provision of the Services. Professor Avi Domb of The Hebrew University of Jerusalem will lead the development efforts provided by Yissum.

"New To The Street" Heads to Florida for Press Conference With Governor Rick Scott and Oakridge Global Energy Solutions, Inc. -- OTCQB: OGES
Marketwired - Tue Oct 06, 12:05PM CDT
"New To The Street" announces with great excitement that it taped Florida's Governor Rick Scott's press conference at the headquarters of one of their feature companies, Oakridge Global Energy Solution, Inc. (OTCQB: OGES). This interview featured Governor Scott speaking about the importance of manufacturing in the USA, and Oakridge Global's commitment to "Made in America." "New To The Street's" Executive Producer, Joyce Glicker, together with Anchor, Erica Ferrari, attended this important press conference.
TWTR: 18.67 (+0.12)

Accurexa to Present at 2015 Stem Cell Meeting on the Mesa
ACCESSWIRE - Mon Sep 28, 7:01AM CDT
NEWARK, DE / ACCESSWIRE / September 28, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that George Yu, MD, President & CEO, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.

"New To The Street" Announces Upcoming Interviews With New Clients & Recurring Clients
Marketwired - Wed Sep 23, 2:10PM CDT
"New To The Street" is excited to announce its current line-up for the taping of their newest T.V. series, set for October 22, 2015 at their state of the art studios in New York City, New York.
TWTR: 18.67 (+0.12)

Professor Robert Langer Advises Accurexa in the Development of its ACX-31 Program
ACCESSWIRE - Thu Sep 03, 7:47AM CDT
NEWARK, DE / ACCESSWIRE / September 3, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies that can deliver therapeutics directly into the brain, announced today that Professor Robert Langer agreed to advise the Company in the development of its ACX-31 Program for the local delivery of temozolomide in combination with BCNU, both chemotherapeutics, in the treatment of brain tumors.

Accurexa to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
ACCESSWIRE - Tue Sep 01, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / September 1, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies that can deliver therapeutics directly into the brain, announced today that it will present at the 17th Annual Rodman & Renshaw Global Investment Conference taking place from September 8-10, 2015 at the St. Regis Hotel in New York City.

"New To The Street" Begins Working With Twitter to Promote Clients Videos on Twitter's Beta Video Platform
Marketwired - Tue Aug 25, 3:15PM CDT
"New To The Street" has just started sharing their clients' videos, marketing with key words to specific demographics on Twitter's (NYSE: TWTR) beta platform.
TWTR: 18.67 (+0.12)

Accurexa Licenses Combination of Local Temozolomide with Local BCNU Patent
ACCESSWIRE - Wed Aug 12, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / August 12, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it has entered into an exclusive license agreement ("ACL License" with Accelerating Combination Therapies LLC ("ACL" in regards to the exclusive licensing of the issued U.S. Patent No. 8,895,597 B2 Combination of Local Temozolomide with Local BCNU ("Patent Rights". ACL is beneficially owned by the original Patent Rights holders and Inventors Henry Brem et al. ("Inventors" who assigned the Patent Rights to ACL. Henry Brem is the Harvey Cushing Professor of Neurosurgery, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief at The Johns Hopkins University, and invented and developed Gliadel(R) wafers to deliver local chemotherapy to brain tumors.

Accurexa Appoints William Callahan to Its Board of Directors
ACCESSWIRE - Thu Jul 02, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / July 2, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that William Callahan has been appointed to its Board of Directors, effective July 1, 2015.
DEPO: 20.94 (+0.21)

"New To The Street" Introduces Five Companies on the Next Two Shows
Marketwired - Thu Jun 25, 8:02AM CDT
"New To The Street" just completed shooting two shows in their state of the art NYC studios.

Accurexa Announces Equity Financing of $2.25 Million
ACCESSWIRE - Wed Jun 17, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 17, 2015 / Accurexa Inc. ("Accurexa" or the "Company", (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, today announced that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of 2,250 shares of the Company's convertible preferred stock for gross proceeds to the Company of $2,250,000.

Accurexa Files 501(k) with FDA; Share Skyrocket to 2015 Highs - Analyst Brief by BrokerBank Securities
PR Newswire - Wed Jun 17, 6:00AM CDT
Accurexa Inc. (OTCQB: ACXA) a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device. The Company's BranchPoint device was invented to deliver therapeutics, such as stem cells, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration. The current standard of care is the use of straight, rigid needles which increase the risk of bleeding, stroke or reflux of therapeutics. Accurexa's system helps minimize this risk.

Accurexa Submits its BranchPoint Device to FDA for 510(k) Clearance
ACCESSWIRE - Mon Jun 15, 7:00AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it has filed a submission with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its BranchPoint device.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 290

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 169

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 136

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading
Moody's Upgrades Phillips Edison to Baa2 Rating with Stability

Updated Category News Views 131

Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...

Continue Reading
Quantum Stocks Soar Amid Rumored Federal Investments

Updated Category News Views 222

Quantum Computing Stocks on the Rise Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) have experienced remarkable increases in pre-market trading. IonQ rose by 13.71%, Rigetti by 11.67%, and D-Wave surged by an impressive 15.90%. This surge comes as there are reports suggesting the federal government may be considering...

Continue Reading
Unlocking Success: How a One-Hour Morning Routine Can Transform Lives

Updated Category News Views 384

The Transformative Power of a Screen-Free Morning Jeff Bezos, the visionary behind Amazon, emphasizes the importance of a structured morning without distractions. His approach encourages starting the day without diving into screens, allowing for a calm and focused beginning. Understanding Bezos' Morning Ritual Instead of beginning his day with devices, Bezos opts for...

Continue Reading
Nokia's Strategic Moves: Infinera Acquisition and Stock Insights

Updated Category News Views 186

Nokia's Evolution in Telecom and Network Solutions Nokia Oyj is a global leader in telecom equipment and offers comprehensive network infrastructure solutions. While it once dominated the mobile phone market, Nokia has since repositioned itself as an essential player in the deployment and support of 5G and 4G networks. Its main competitor, Telefonaktiebolaget LM Ericsson,...

Continue Reading